Tada

Thanks for the corrections.

One issue I am not not clear on due to sparse management communication is from whom and how much the trial dollars will be and will come from and whether or not RVX will retain any future interest in Zen-3694 - evidently negotiations are in progress. You are saying that Zen capital will sell rights to Zen-3694 in part or whole for various therapies in clinical trials but still retain the patent rights on NUT which may soon get to market for orphan status. Hopefully these negotiations morph into something bigger which includes RVX.

Chicagoest